# A Study on the Treatment Strategy of NVG Secondary to PDR

> **NCT05156021** · NA · COMPLETED · sponsor: **Ruijin Hospital** · enrollment: 39 (actual)

## Conditions studied

- Neovascular Glaucoma
- Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** anti-VEGF

## Key facts

- **NCT ID:** NCT05156021
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-12
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156021, "A Study on the Treatment Strategy of NVG Secondary to PDR". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05156021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*